PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15

Current Edition

Cell and Gene Therapy

Upcoming Events

PEGS Europe – 24.07.2025
BIO-Europe 2025 – 10.07.2025
Cell 2025 – 30.05.2025
Cell Leaders Awards – 30.05.2025

Advertisement

Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault – 18.03.2025
Biopharma Group – 19th March 2025
Light Cast – 17.07.2025

Regulatory Impact Assessment is Obvious Next Target for GenAI, Experts Conclude 

When anything changes to a product’s make-up or manufacture, a whole chain of events is triggered, starting with an assessment of the regulatory impact in each regulatory jurisdiction, swiftly followed by required actions. Any delay or omission could be costly, so smart process automation offers attractive potential. Regulatory experts Preeya Beczek and ArisGlobal’s Agnes Cwienczek scope the opportunity. 

AI’s potential to transform speed and efficiency, and improve accuracy, has already been demonstrated across a number of Regulatory use cases. These early successes have instilled industry confidence in what the technology can do. Next in companies’ sights is regulatory impact assessment as part of overall product change control (the structured process to assess, document and implement changes to products). Intensifying pressure to bring medicines and updates to market quickly is galvanising Regulatory teams to work in more streamlined ways. Without recourse to artificial intelligence (AI), this is becoming increasingly unviable.

Newcells 3 June 2024, 15:12
Aldevron: 16th January 2025
Drug Discovery 2025, ELRIG – 04.07.2025
Richter: Wed 23 October 2024, 09:03
Tosoh – 29.04.25
Asychem – 10.04.2025
Taconic Biosciences – 29.04.25
Steribar – 12.05.2025
InsideReg – 29.07.2025
Crown Bioscience 08.09.2025